Gland Pharma Limited
NSE: GLANDMarket Closed • NSE
Day range
52 week range
Gland Pharma Limited closed at INR3043.40 (-0.75%) on volume 0.47x its 20-day average, trading 4.02% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -13.6% QoQ
2026-08-11
DIVIDEND Announced
Dividend - Rs 20 Per Sh
2025-08-14
DIVIDEND Announced
Dividend - Rs 18 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 15.1%
High Cash Flow Conversion: CFO/PAT averaged 1x over last 3 years
Risks
Elevated Leverage Burden: Debt-to-Equity stands at 2.74x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 11 Aug 2026 | Dividend | ₹20.00 / share | — | 11 Aug 2026 |
| 14 Aug 2025 | Dividend | ₹18.00 / share | — | 14 Aug 2025 |
| 16 Aug 2024 | Dividend | ₹20.00 / share | — | 16 Aug 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 06 Aug 2021 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
IndiaHealthcare
Is Gland Pharma Limited Shariah compliant?
Gland Pharma Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.57%) complies with AAOIFI threshold (≤ 33%).
What is Gland Pharma Limited's current valuation relative to peers?
Gland Pharma Limited trades at a P/E of 44.4x compared to the sector median of 37x, and a Price-to-Book of 4.8x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 2.74x and a Net Debt to EBITDA ratio of 0.17x. Interest coverage is 49.4x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 2.7% while net profit growth averaged 8%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.